Objective The purpose of this study is to explore the supplementation of deep-sea fish oil ω- The relationship between the improvement of psychiatric symptoms and the reduction of the risk of metabolic syndrome in patients with first-episode schizophrenia in the acute phase of 3 fatty acids.
Methods From September 2021 to September 2022, 54 patients who met the ICD-10 diagnostic criteria for schizophrenia and took antipsychotic drugs in Zibo Mental Health Center were randomly assigned to fish oil group (n=30) and placebo group (n=24). Before treatment and at the 4th, 8th and 12th weeks after treatment, the patients in the two groups were scored with Positive and Negative Syndrome Scale (PANSS), Modified Over Aggression Scale (MOAS) and Brief Psychiatric Rating Scale (BPRS), at the same time, the cognitive function scores of the two groups of patients before and after treatment were evaluated with the schizophrenia cognitive function assessment scale (MCCB), and the blood biochemical indicators of the patients were collected, and the levels of blood cholesterol, triglycerides, High-density lipoprotein (HDL), low-density lipoprotein (LDL) were recorded.
Results The results showed that the PANSS, BPRS, and MOAS scores of both groups of patients decreased at week 4, and there was no statistically significant difference between the two groups (P>0.05); at weeks 8 and 12, the score of the fish oil group was significantly lower than that of the placebo group, and there was a statistical difference between the two groups (P<0.05). Blood cholesterol, triglycerides, and LDL all increased at week 4, and there was no statistically significant difference between the two groups (P>0.05); at weeks 8 and 12, the placebo group was higher than the fish oil group, and there was a statistical difference between the two groups (P<0.05). HDL decreased at week 4, and there was no statistically significant difference between the two groups (P>0.05); at weeks 8 and 12, the decrease in fish oil group was lower than that in placebo group, and there was a statistical difference between the two groups (P<0.05). after the intervention, the related indicators of MCCB scores of patients in both groups increased to varying degrees, and the scores of Working memory, speech learning and problem reasoning dimensions of patients in the fish oil group increased significantly compared with those in the placebo group (P<0.05).
Conclusion Take deep-sea fish oil every day ω-3 fatty acids significantly improve the mental symptoms of first-episode schizophrenia patients in the acute phase, especially reducing impulsive and aggressive behavior, improving cognitive function, and reducing the risk of metabolic syndrome.
